Treating diabetes mellitus in Prader–Willi syndrome with Exenatide
Abstract We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader–Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2011-04, Vol.92 (1), p.e1-e2 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e2 |
|---|---|
| container_issue | 1 |
| container_start_page | e1 |
| container_title | Diabetes research and clinical practice |
| container_volume | 92 |
| creator | Seetho, Ian W Jones, Gavin Thomson, George A Fernando, Devaka J.S |
| description | Abstract We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader–Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes mellitus in Prader–Willi syndrome. |
| doi_str_mv | 10.1016/j.diabres.2010.12.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_862603889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168822710005991</els_id><sourcerecordid>862603889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-43b78b56d5cccbfb63cf8f4778b455403a3c41bf5311e6b8c9846cb3c8e4b4933</originalsourceid><addsrcrecordid>eNqFkclOwzAURS0EgjJ8Aig7Vi2e62xAqIwSEkiAWFqx8wIuGcBOgO74B_6QL8GhhQUbVrauzn3PvhehbYJHBBO5Nx3lLjMewojiXqMjjNMlNCBqTIeK0vEyGkROfd_X0HoIU4yxZFysojVKoiioHKCjGw9Z6-r7pB8HLYSkgrJ0bRcSVydXPsvBf75_3LkoJmFW576pIHl17UNy_AZ19OawiVaKrAywtTg30O3J8c3kbHhxeXo-ObwYWk7SdsiZGSsjZC6staYwktlCFXwcRS4ExyxjETSFYISANMqmiktrmFXADU8Z20C787lPvnnuILS6csHG52Y1NF3QSlKJmVJpJMWctL4JwUOhn7yrMj_TBOs-Pz3Vi_x0n58mVMf8om9nsaEzFeS_rp_AInAwByD-88WB18E6qC3kzoNtdd64f1fs_5lgS1c7m5WPMIMwbTpfxxA10SEa9HVfYt8hifWJNCXsC5G-ma0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>862603889</pqid></control><display><type>article</type><title>Treating diabetes mellitus in Prader–Willi syndrome with Exenatide</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Seetho, Ian W ; Jones, Gavin ; Thomson, George A ; Fernando, Devaka J.S</creator><creatorcontrib>Seetho, Ian W ; Jones, Gavin ; Thomson, George A ; Fernando, Devaka J.S</creatorcontrib><description>Abstract We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader–Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes mellitus in Prader–Willi syndrome.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2010.12.009</identifier><identifier>PMID: 21227526</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Diabetes mellitus ; Diabetes Mellitus - drug therapy ; Endocrinology & Metabolism ; Exenatide ; Female ; Ghrelin ; Ghrelin - therapeutic use ; Humans ; Obesity ; Peptides - therapeutic use ; Prader-Willi Syndrome - drug therapy ; Prader–Willi syndrome ; Venoms - therapeutic use ; Young Adult</subject><ispartof>Diabetes research and clinical practice, 2011-04, Vol.92 (1), p.e1-e2</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-43b78b56d5cccbfb63cf8f4778b455403a3c41bf5311e6b8c9846cb3c8e4b4933</citedby><cites>FETCH-LOGICAL-c419t-43b78b56d5cccbfb63cf8f4778b455403a3c41bf5311e6b8c9846cb3c8e4b4933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168822710005991$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21227526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seetho, Ian W</creatorcontrib><creatorcontrib>Jones, Gavin</creatorcontrib><creatorcontrib>Thomson, George A</creatorcontrib><creatorcontrib>Fernando, Devaka J.S</creatorcontrib><title>Treating diabetes mellitus in Prader–Willi syndrome with Exenatide</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>Abstract We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader–Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes mellitus in Prader–Willi syndrome.</description><subject>Adult</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Endocrinology & Metabolism</subject><subject>Exenatide</subject><subject>Female</subject><subject>Ghrelin</subject><subject>Ghrelin - therapeutic use</subject><subject>Humans</subject><subject>Obesity</subject><subject>Peptides - therapeutic use</subject><subject>Prader-Willi Syndrome - drug therapy</subject><subject>Prader–Willi syndrome</subject><subject>Venoms - therapeutic use</subject><subject>Young Adult</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkclOwzAURS0EgjJ8Aig7Vi2e62xAqIwSEkiAWFqx8wIuGcBOgO74B_6QL8GhhQUbVrauzn3PvhehbYJHBBO5Nx3lLjMewojiXqMjjNMlNCBqTIeK0vEyGkROfd_X0HoIU4yxZFysojVKoiioHKCjGw9Z6-r7pB8HLYSkgrJ0bRcSVydXPsvBf75_3LkoJmFW576pIHl17UNy_AZ19OawiVaKrAywtTg30O3J8c3kbHhxeXo-ObwYWk7SdsiZGSsjZC6staYwktlCFXwcRS4ExyxjETSFYISANMqmiktrmFXADU8Z20C787lPvnnuILS6csHG52Y1NF3QSlKJmVJpJMWctL4JwUOhn7yrMj_TBOs-Pz3Vi_x0n58mVMf8om9nsaEzFeS_rp_AInAwByD-88WB18E6qC3kzoNtdd64f1fs_5lgS1c7m5WPMIMwbTpfxxA10SEa9HVfYt8hifWJNCXsC5G-ma0</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Seetho, Ian W</creator><creator>Jones, Gavin</creator><creator>Thomson, George A</creator><creator>Fernando, Devaka J.S</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Treating diabetes mellitus in Prader–Willi syndrome with Exenatide</title><author>Seetho, Ian W ; Jones, Gavin ; Thomson, George A ; Fernando, Devaka J.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-43b78b56d5cccbfb63cf8f4778b455403a3c41bf5311e6b8c9846cb3c8e4b4933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Endocrinology & Metabolism</topic><topic>Exenatide</topic><topic>Female</topic><topic>Ghrelin</topic><topic>Ghrelin - therapeutic use</topic><topic>Humans</topic><topic>Obesity</topic><topic>Peptides - therapeutic use</topic><topic>Prader-Willi Syndrome - drug therapy</topic><topic>Prader–Willi syndrome</topic><topic>Venoms - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seetho, Ian W</creatorcontrib><creatorcontrib>Jones, Gavin</creatorcontrib><creatorcontrib>Thomson, George A</creatorcontrib><creatorcontrib>Fernando, Devaka J.S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seetho, Ian W</au><au>Jones, Gavin</au><au>Thomson, George A</au><au>Fernando, Devaka J.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treating diabetes mellitus in Prader–Willi syndrome with Exenatide</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>92</volume><issue>1</issue><spage>e1</spage><epage>e2</epage><pages>e1-e2</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>Abstract We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader–Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes mellitus in Prader–Willi syndrome.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>21227526</pmid><doi>10.1016/j.diabres.2010.12.009</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2011-04, Vol.92 (1), p.e1-e2 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_862603889 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Diabetes mellitus Diabetes Mellitus - drug therapy Endocrinology & Metabolism Exenatide Female Ghrelin Ghrelin - therapeutic use Humans Obesity Peptides - therapeutic use Prader-Willi Syndrome - drug therapy Prader–Willi syndrome Venoms - therapeutic use Young Adult |
| title | Treating diabetes mellitus in Prader–Willi syndrome with Exenatide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A53%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treating%20diabetes%20mellitus%20in%20Prader%E2%80%93Willi%20syndrome%20with%20Exenatide&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Seetho,%20Ian%20W&rft.date=2011-04-01&rft.volume=92&rft.issue=1&rft.spage=e1&rft.epage=e2&rft.pages=e1-e2&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2010.12.009&rft_dat=%3Cproquest_cross%3E862603889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=862603889&rft_id=info:pmid/21227526&rft_els_id=1_s2_0_S0168822710005991&rfr_iscdi=true |